3P Biopharmaceuticals

Prior to its merger into 3PBIOVIAN in February 2024, 3P Biopharmaceuticals was a leading Spanish CDMO specializing in process development and cGMP manufacturing of biologics and cell therapies. It supported global biotech/pharma clients from preclinical through commercial supply. The company contributed to the manufacture of Spain’s first biosimilar used post-cancer chemotherapy, COVID‑19 vaccine candidates with French/Swedish partners, the world’s only canine Leishmania vaccine, and an EMA-approved equine mumps vaccine. It experienced rapid growth (~30% annually), had over €33M turnover by end of 2020, employed more than 350 people by late 2022, and operated state-of-the-art facilities.